Adaptive Biotechnologies Corp. (Nasdaq: ADPT) and Microsoft Corp. (Nasdaq: MSFT) announced they will leverage their existing partnership mapping population-wide adaptive immune responses to diseases at scale to study COVID-19.

Finding the relevant immune response signature may advance solutions to diagnose, treat and prevent the disease, augmenting existing research efforts that primarily focus on the biology of the virus.

These data will be made freely available to any researcher, public health official or organization around the world via an open data access portal.

The immune response signature found from the initial discovery work and the initial set of samples will be uploaded to the open data access portal.

Timing and enrollment details about the upcoming study and the open data access portal will be coming soon. | To read full story, visit https://startuparound.com/read/1584831714.5589128/Adaptive-Biotechnologies-and-Microsoft-Partner-To-Decode-COVID-19-Immune-Response-and-Provide-Open-Data-Access?ref=audio_experience